A pharmaceutical company can have MHRA approval, a positive NICE opinion, and a differentiated product, and still find that patients are not accessing the treatment a year after launch. The post-approval stage is where UK launches are won or lost, and for companies entering the market without an established commercial presence, the gap between regulatory success and real-world patient access is an operational challenge.
The UK has become a more attractive launch environment over the past twelve months. The 2026 VPAG reset brought the rebate rate down to 14.5%, a real improvement on the 22.9% peak that had made the commercial case for UK investment difficult to justify for smaller companies. NICE cost-effectiveness thresholds rose in April 2026. There is positive momentum, but improved national conditions don’tsolve the local access problem, and for a company building its UK commercial capability from scratch, that's where most launches stall.
The NHS looks like a single system but functions as multiple. National regulatory approval and even NICE guidance sit at the top of a layered decision-making structure that becomes progressively more granular and less predictable as it moves towards the patient.
For most products, the pathway runs through NICE, then NHS England commissioning policy (for specialised products), then the Integrated Care Boards (ICBs), then hospital formulary committees, then individual prescribers. Each layer has its own timeline, its own criteria, and its own priorities. A new market entrant without existing relationships at any of these levels is navigating them all simultaneously.
For specialised therapies, including cell and gene therapies, complex biologics, and rare disease treatments, the post-approval journey is even more complex. National reimbursement is a prerequisite, but it does not guarantee that the product reaches the hospital that treats the relevant patients, let alone the patient themselves.
Experience from recent specialised product launches points to a consistent pattern: national reimbursement is agreed, and then the work begins. The financial terms agreed at national level have to be understood, interpreted, and operationalised by the local systems that control actual prescribing. In the UK context, that means ICBs, NHS Trust pharmacy departments, and in some cases individual clinical teams who have never encountered the product before.
That landscape is set to become somewhat more consistent. The Single National Formulary, due to go live in 2027, is designed to replace local formulary variation with a single national standard for which medicines are available across the NHS. Once implemented, a positive SNF listing will carry greater weight than the current patchwork of ICB-level decisions. For a company planning a launch in 2026, however, the SNF is not yet a factor in the access picture, and local pull-through work remains as important as ever.
Outcome-based agreements, increasingly common for high-cost innovative therapies, add another layer of complexity. Payers frequently demand them, particularly when published clinical trial data covers only a few years, and the company asserts durable long-term benefit. But agreeing the principle of an outcome-based agreement and agreeing the operational detail are different problems. What counts as treatment failure? Who judges efficacy? What is the mechanism and timeline for any rebate? These questions don’t resolve themselves after a national deal is signed. They require people with the right expertise to work through them, payer by payer.
For a company without an existing UK team, this is the moment when the absence of infrastructure becomes most concerning, because these conversations require sustained, knowledgeable local presence, not occasional head-office visits.
For complex therapies, particularly those involving a single high-cost administration, there is an additional barrier between national reimbursement and patient access: the treatment centre must be ready to deliver.
Centre readiness has several dimensions. The clinical team needs to be trained and confident in the treatment protocol. Ordering, storage, and administration logistics have to be planned and rehearsed, including edge cases such as what happens if something goes wrong during the preparation of, for example, an expensive biologic. The patient pathway needs to be mapped: who screens the patient, who does the education, where the administration takes place, and who handles follow-up monitoring. In hub-and-spoke models, common in the UK for specialised therapies, a small number of specialist centres (hubs) carry out the most complex elements of treatment, such as the administration of a gene therapy or a complex biologic infusion, while a wider network of local centres (spokes) handles patient screening, education, and follow-up monitoring closer to home. The responsibilities of each hub and its associated spoke centres need to be agreed in writing before the first patient is treated.
None of this happens automatically. It requires pharmaceutical company staff with the time, expertise, and local relationships to sit alongside clinical teams and work through the detail. A company that treats centre readiness as something the hospital will sort out tends to find its launch timetable slipping by months.
For products that involve a significant lifestyle adjustment, or a one-time decision that cannot easily be reversed, patient education is an integral part of the commercial programme. In gene therapy, for example, patients making a permanent treatment choice need to understand not just the clinical proposition but the practical implications for how they live: what they can and cannot do before and after treatment, why it matters, and what monitoring is required afterwards.
This is not a job that a small central team can do at scale. Patient advocacy groups, clinical teams at treatment centres, and specialist nurses all play a role, and pharmaceutical company staff must proactively coordinate these relationships. The workload here tends to surprise companies accustomed to launching conventional products, where the patient education burden is lower, and the prescriber community is larger and more diffuse.
For a company entering the UK without existing commercial and medical infrastructure, there are three broad models for addressing these challenges.
Hiring a full internal UK medical and commercial team (medical affairs, market access, field force, patient services) gives the most control and builds institutional knowledge. It is also the slowest and most capital-intensive option. Recruiting the right people at senior market access and KAM levels in the UK takes time, and a team assembled at pace for a single launch often lacks the depth of NHS relationships that comes from years in market.
For some products, the most practical route is a co-promotion or licensing arrangement with a company that already has UK infrastructure. This trades margin and control for speed and existing relationships. It works well where the partner's existing therapeutic area and customer base align closely with the product being launched. Where they do not, the partnership tends to produce a launch that looks commercially active but lacks the sustained specialist engagement the product requires.
Contract commercial and medical teams, including outsourced field forces, medical science liaison teams, and market access support, have become a well-established model in the UK. The market for this kind of support has matured considerably; providers now offer significant flexibility on team size, geographic coverage, and contract structure, with field-ready teams deployable within eight to twelve weeks in most cases.
The outsourced model works particularly well for companies launching a first or second product in the UK, where the investment case for a permanent full commercial infrastructure is not yet established. It also works for specialised therapies with small but high-value patient populations, where a compact, highly skilled team of five to ten people is more appropriate than a conventional field force.
What makes the outsourced model work, when it works well, is the same thing that makes any commercial team effective: people with deep therapy-area knowledge, established NHS relationships, and the ability to operate with the independence afforded by a lean, UK-focused structure. CHASE builds outsourced teams exclusively within the UK, drawing on a network developed over 25 years in life sciences, which means the individuals deployed typically bring both the specialist expertise and the local stakeholder relationships a new market entrant most needs. The quality of the brief given to any outsourced partner matters, as does clarity on the specific profile required, but the structural advantages of the model- speed to deployment, flexibility to scale, and reduced overhead risk- hold regardless of company size or therapy area.
Whatever model a new market entrant chooses, the profile of the people needed for a UK launch in a specialised or rare-disease setting requires market-access experience at ICB and NHS England levels. KAMs working at this level must understand commissioning structures, formulary processes, and NHS budget cycles, not just product features. MSL profiles, where relevant, need genuine peer-level scientific credibility with clinical specialists.
For complex therapy launches, the people who make the difference in the first twelve to eighteen months are rarely generalists. They tend to be individuals who have worked in the relevant therapy area, understand the NHS pathway for that patient population, and have existing relationships with the key treatment centres. Finding those people, and finding them quickly, is often the rate-limiting factor for a company that has reached launch readiness in every other dimension.
One consistent observation from companies that have successfully launched in specialised areas is that the commercial groundwork starts earlier than most organisations plan for. Market access engagement with NHS England and key ICBs, patient pathway mapping, treatment centre identification, and relationship-building with patient advocacy groups all take time to bear fruit. Starting that work two to three years before anticipated approval gives a company the relationships and intelligence it needs to move quickly once a positive NICE decision is made. Starting six months before often meansthe first year of commercial activity is spent catching up.
The UK market rewards preparation. Companies that assume national reimbursement will translate into local patient access without sustained commercial effort, typically find otherwise, at the cost of patients who could have benefited sooner.
CHASE provides outsourced commercial and medical teams, specialist recruitment, and market access support to pharmaceutical and medtech companies operating in the UK. If you are planning a UK launch and want to discuss your commercial and medical model, get in touch.
Explore our latest thinking, event updates and industry insights to stay informed.
Field team management in the pharmaceutical and medtech sectors in the era of the NHS 10-Year Plan, ICB Blueprint and Medium Term Planning Framework
The UK medtech market is undergoing profound and rapid change. Success demands local knowledge, a focus on patient pathways, and real-world evidence.
Q4 is a challenge for pharma and medtech field sales teams with limited access to NHS key decision makers for value- based chats and deferred product adoption.
.svg)
